Navigation Links
Delcath Appoints Gregory Gores, M.D. to Medical Advisory Board
Date:12/21/2011

NEW YORK, Dec. 21, 2011  /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH) appointed Gregory Gores, M.D. to the Company's Medical Advisory Board.

"As a widely respected hepatologist and 2011 President of the International Liver Cancer Association (ILCA), Dr. Gores will contribute a wealth of clinical knowledge on hepatotoxicity and drug induced liver pathology to our Medical Advisory Board," said Eamonn P. Hobbs, CEO & President of Delcath Systems.  "His insight will help provide valuable support to the commercialization of the Delcath Hepatic CHEMOSAT® Delivery System in Europe and the rest of the world, as well as to our regulatory process in the United States."

Dr. Gores is the Reuben R. Eisenberg Endowed Professor in Gastroenterology and Hepatology, professor of Medicine, and chair of the Division of Gastroenterology and Hepatology at the Mayo Clinic in Rochester, Minnesota. His research is focused on the fundamental mechanisms underpinning cell death in the liver, employing models relevant to human disease. He has published more than 400 original articles, chapters, reviews, and editorials. Dr. Gores serves on the editorial boards for the American Journal of Physiology, American Journal of Gastroenterology, and Nature Reviews in Clinical Gastroenterology and Hepatology and is a past Associate Editor for Hepatology.

Dr. Gores has served as a standing member for two NIH Study Sections and recently chaired the Hepatobiliary Pathobiology Study Section. He has served on the Grants Review Committee for the American Liver Foundation. Dr. Gores is a past president of the American Association for the Study of Liver Diseases and has participated in many activities and committees of this organization. He has been elected into the honorific societies of the American Society for Clinical Investigation and the American Association of Physicians. H
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
3. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
4. Delcath Adds Dr. Pamela R. Contag to Its Board of Directors
5. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
7. Data Safety Monitoring Board Unanimously Recommends Continuation of Delcaths Phase III Clinical Trial
8. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
9. Delcath Systems, Inc. Completes Phase III Study Enrollment
10. Delcath Systems Begins Data Analysis of Phase III Trial
11. Delcath Systems, Inc. to Present at the 12th Annual Needham Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... DIEGO y PARÍS, 24 de mayo ... VOLC ), un destacado desarrollador y fabricante de ... mejorar la diagnosis y tratamiento de la enfermedad ... preliminares del ensayo ADVISE ( Ad enosine ... E valuation) II durante la sesión de ...
(Date:5/23/2013)... May 23, 2013 Amgen (NASDAQ: AMGN ... Annual  Healthcare Conference on Thursday, May 30, 2013, at the ... at 9:20 a.m. Eastern Daylight Time. Arvind Sood ... present at the conference. Live audio of the presentation can ... www.amgen.com , under Investors. A replay of the webcast will ...
(Date:5/23/2013)... Nephros, Inc. (OTC Bulletin Board: ... develops and sells high performance liquid purification ultrafilters, announced ... addition, the concurrent temporary reduction in exercise price for ... 2013. Nephros estimates that it will receive ... A portion of the proceeds will be used for ...
Breaking Medicine Technology:Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4
... 13, 2011 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ... CSKI ), a leading fully integrated pharmaceutical company ... ("PRC"), today announced that it held its 2011 Annual ... 2011, in Harbin, PRC. At the Annual ...
... 2011 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") ... in-vitro diagnostic ("IVD") company, today announced that China,s State ... Company,s real-time PCR-based V-Ki-ras2 Kirsten rat sarcoma viral oncogene ... companion diagnostic test for the use of a targeted ...
Cached Medicine Technology:China Sky One Medical, Inc. Elects Board Directors at its Annual Shareholders Meeting 2China Medical Technologies Receives SFDA Approval for its PCR-based KRAS Assay for Colorectal Cancer Targeted Drug 2
(Date:5/23/2013)... May 23, 2013 Susquehanna Health ... offering a comprehensive babysitting training course for adolescents age ... developed by Indianapolis pediatrician Dr. Patricia Keener after a ... of an adult sitter who didn’t know how to ... development program with a medical basis that aims to ...
(Date:5/23/2013)... - Even while being dragged to its destruction ... fires away, sending signals that thwart the development ... reported in an early online publication at ... often encountered by tumors, the epidermal growth factor ... an international team led by scientists at The ...
(Date:5/23/2013)... Clinic researchers have used next generation genomic analysis to ... tumors have similar genetic origins, which may help in ... the journal Cancer Research . , "This is ... generation sequencing in adjacent Gleason patterns in the same ... pathology," says ,John Cheville, M.D., Mayo Clinic pathologist and ...
(Date:5/23/2013)... Rottenstein Law Group LLP, a New York-based nationwide mass ... Center at http://www.rotlaw.com/tylenol , dedicated to issues that ... filing lawsuits. , The painkiller Tylenol (acetaminophen) has ... to a 2009 report from the U.S. Food and ... warned consumers against using more than the recommended dose ...
(Date:5/23/2013)... Dr. Katherine Ahn is proud to ... County, OCCares , will hold its first community event ... details are as follows: , Sunday May 26th, 2013 from ... Garden Grove, CA 92843 , The benefit celebration will feature ... Charmaine & Jonathan Thulin. There will also be piano, ...
Breaking Medicine News(10 mins):Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 2Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 3Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 2Health News:When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs 3Health News:Mayo Clinic genomic analysis lends insight to prostate cancer 2Health News:Rottenstein Law Group LLP Now Accepting Tylenol Cases, Announces New Tylenol Lawsuit Information Center 2Health News:Dr. Katherine Ahn is Proud to Announce the Launch Her Family's New Charity OCCares 2Health News:Dr. Katherine Ahn is Proud to Announce the Launch Her Family's New Charity OCCares 3
... failure by official bodies to halt the distribution of ... been incidents caused by E. coli contamination in ... food. , Around 200 persons were affected ... was the collapse of both kidneys of a three-year-old ...
... huge doping scam burst into the open in Paris, ... suspended for three months by the// Californian state authorities. ... the Bay Area Laboratory Co-Operative that allegedly provided steroids ... placed on five years' probation and ordered to undergo ...
... increased rates of serious infections caused by strains ... the current childhood pneumococcal vaccine,// according to a ... conjugate vaccine (PCV7), Alaska Native children and adults ... compared with non–Native Alaskans. Introduction of PCV7 into ...
... Stroke patients in rural hospitals can get safe, effective ... a doctor from a larger hospital is on the ... implications for overcoming barriers to optimal stroke care in ... of this treatment over the telephone appears to be ...
... experience hot flashes: unpredictable, sometimes disruptive, periods of intense ... generations of physicians have prescribed hormones to reduce these ... causes of hot flashes. ,Three new studies explore ... contributing to – or lessening – the intensity and ...
... medical representatives needs no introduction. The motivation for such ... and boardrooms, where jet-setting corporate executives are given their ... sheer bottom-line figures, the dynamic medical rep gets to ... medical representatives first create a ready reckoner of the ...
Cached Medicine News:Health News:U.S Officials Worried Over Failure In Preventing Food Contamination 2Health News:US Psychiatrist Suspended from Practicing Medicine for Involvement in Doping Scam 2Health News:US Psychiatrist Suspended from Practicing Medicine for Involvement in Doping Scam 3Health News:Increase in Pneumococcal Infections That are Not Covered by Vaccine 2Health News:Hot Flashes: Studies Explore the Various Possibilities Involved 2Health News:Hot Flashes: Studies Explore the Various Possibilities Involved 3Health News:Art of Establishing a Bond to Sell a Brand – Medical Reps Show the Wa 2
... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
... a 1-step, hand-held, point-of-care device for the qualitative ... urine. The TOX/See device can detect up ... in 3 to 8 minutes and requires only ... is individually packaged to maximize convenience and ease ...
... Sugar-Chex Linearity is a whole blood ... reportable range of the most popular ... recommendations of using a control matrix ... Linearity is packaged in ready-to-use dropper ...
Medicine Products: